Mitsubishi Tanabe Pharma Corporation
http://www.mt-pharma.co.jp/e/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mitsubishi Tanabe Pharma Corporation
Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices
A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.
Lykos’s Knockback Could Be An Opportunity For Rivals
The group intends to appeal the US FDA’s rejection of its MDMA-based PTSD therapy, midomafetamine, but other psychedelics could advance in the meantime.
Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts
Several major Japanese firms, including Takeda, are planning layoffs at home and elsewhere as they make efforts to streamline their business and costs and cope with R&D and commercial challenges.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- BIXEN Corporation
- Medicago Inc.
- Mitsubishi Tanabe Pharma America, Inc. (MTPA)
- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
- Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
- NeuroDerm, Ltd. (NDRM)
- PT Mitsubishi Tanabe Pharma Indonesia
- Mitsubishi Tanabe Pharma (Thailand)
- MT Pharma Singapore PTE. Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- Tanabe Research Laboratories U.S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice